by Kyle | May 29, 2024 | Press Release
State of California Department of Public Heath Food and Drug Branch Issues the Company a License for Manufacturing of its Diagnostic Assays SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the...
by Kyle | Mar 27, 2024 | Press Release
Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM’s Diagnostic Research Programs in Dry Eye Disease and Parkinson’s SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an...
by Kyle | Feb 20, 2024 | Press Release
The Company’s Commercialization Partner Verséa Ophthalmic Places Re-stock Order of AXIM’s Digital Assay Reader SAN DIEGO, CA, Feb. 20, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”),...
by Kyle | Dec 20, 2023 | Press Release
Leading Diagnostic Healthcare Company Signs Contract Manufacturing Agreement in Order to Fulfill Sales of IgE and Lactoferrin DED Diagnostic Assays SAN DIEGO, CA, Dec. 20, 2023 (GLOBE NEWSWIRE) — via NewMediaWire –AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM...
by Kyle | Aug 1, 2023 | Press Release
Leading Diagnostic Healthcare Company Highlights Value Proposition of Expanding IP Portfolio Which Includes 13 Different Filings and Allowances SAN DIEGO–(BUSINESS WIRE)–AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an...
by Kyle | Jul 26, 2023 | News, Press Release
Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-based Point-of-Care (T-POC) Quantitative Testing Platform Business Wire TAMPA, Fla. — July 25, 2023 Verséa™ Ophthalmics, LLC, a division of Verséa Health, Inc. committed to delivering novel, high-value...
